Cross-reactivity in β-Lactam Allergy.
Zagursky RJ, Pichichero ME.
J Allergy Clin Immunol Pract · review; journal article · DOI 10.1016/j.jaip.2017.08.027 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för ceftaroline fosamil. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
24 träffarEfficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model.
Bhalodi AA, Crandon JL, Biek D, Nicolau DP.
Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.01078-12Summary of ceftaroline fosamil clinical trial studies and clinical safety.
File TM, Wilcox MH, Stein GE.
Clin Infect Dis · research support, non-u.s. gov't; review; journal article · DOI 10.1093/cid/cis559Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Lodise TP, Low DE.
Drugs · research support, non-u.s. gov't; review; journal article · DOI 10.2165/11635660-000000000-00000Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
Casapao AM, Steed ME, Levine DP, Rybak MJ.
Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.2012.685718Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model.
Steed ME, Vidaillac C, Winterfield P, Biek D, Rybak MJ.
Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.06185-11Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolates.
Housman ST, Keel RA, Crandon JL, Williams G, Nicolau DP.
Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.06416-11CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.
Friedland HD, O'Neal T, Biek D, Eckburg PB, Rank DR, Llorens L, Smith A, Witherell GW, Laudano JB, Thye D.
Antimicrob Agents Chemother · clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1128/aac.05738-11Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia.
Maselli DJ, Fernandez JF, Whong CY, Echevarria K, Nambiar AM, Anzueto A, Restrepo MI.
Infect Drug Resist · review-article; journal article · DOI 10.2147/idr.s17433Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Singh BN, Dedhiya MG, DiNunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Am J Health Syst Pharm · journal article · DOI 10.2146/ajhp100606Ceftaroline fosamil: A novel anti-Methicillin-resistant Staphylococcus aureus cephalosporin.
Girish C, Balakrishnan S.
J Pharmacol Pharmacother · other; journal article · DOI 10.4103/0976-500x.83298Ceftaroline fosamil: a new broad-spectrum cephalosporin.
Laudano JB.
J Antimicrob Chemother · research support, non-u.s. gov't; review; journal article · DOI 10.1093/jac/dkr095FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
File TM, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley IA, Thye DA, FOCUS 1 investigators.
J Antimicrob Chemother · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1093/jac/dkr096FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Low DE, File TM, Eckburg PB, Talbot GH, David Friedland H, Lee J, Llorens L, Critchley IA, Thye DA, FOCUS 2 investigators.
J Antimicrob Chemother · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1093/jac/dkr097Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
Rank DR, Friedland HD, Laudano JB.
J Antimicrob Chemother · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1093/jac/dkr099Changing needs of community-acquired bacterial pneumonia: experience with ceftaroline fosamil. Preface.
Johnson AP, Leibovici L.
J Antimicrob Chemother · introductory journal article · DOI 10.1093/jac/dkr145Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
Jacqueline C, Amador G, Batard E, Le Mabecque V, Miègeville AF, Biek D, Caillon J, Potel G.
J Antimicrob Chemother · research support, non-u.s. gov't; journal article · DOI 10.1093/jac/dkr019Ceftaroline fosamil: drug profile and clinical data.
Kanafani ZA.
Future Microbiol · journal article · DOI 10.2217/fmb.10.132Ceftaroline fosamil (Teflaro) - a new IV cephalosporin.
Författaruppgift saknas
Med Lett Drugs Ther · journal articlePharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity.
Drusano GL.
J Antimicrob Chemother · research support, non-u.s. gov't; journal article · DOI 10.1093/jac/dkq253CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T, CANVAS 1 investigators.
J Antimicrob Chemother · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1093/jac/dkq254CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T, CANVAS 2 investigators.
J Antimicrob Chemother · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1093/jac/dkq255Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Corrado ML.
J Antimicrob Chemother · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1093/jac/dkq256Ceftaroline fosamil: a novel broad-spectrum cephalosporin.
Bazan JA, Martin SI.
Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2010.46.10.1519172